{
  "symbol": "MRSN",
  "companyName": "Mersana Therapeutics, Inc.",
  "exchange": "NASDAQ",
  "industry": "Biotechnology",
  "website": "http://www.mersana.com",
  "description": "Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.",
  "CEO": "Anna Protopapas",
  "securityName": "Mersana Therapeutics, Inc.",
  "issueType": "cs",
  "sector": "Health Technology",
  "employees": 86,
  "tags": [
    "Health Technology",
    "Biotechnology"
  ]
}